41 results about "Acetónido de fluocinolona" patented technology

A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.

The present invention is a method of the present invention screens a patient with macular edema associated with visual loss for implantation of a sustained release drug-delivery implant that is less invasive than implanting a drug-delivery implant and is minimally invasive. The method comprises injecting a first steroid, eg. triamcinolone acetonide, having anti-inflammatory activity as a bolus into a patient's eye. Patients that experience a reduction in swelling in the retina (typically the macula and preferably the fovia) and improved vision are identified as candidate patients. Candidate patients are patients that are more likely to benefit from the implantation of a sustained release drug-delivery implant into the eye containing a second steroid, for example fluocinolone acetonide.

The invention provides an exterior medicine composition of fluocinolone acetonide and ester of fluocinolone acetonide. The exterior medicine composition comprises the fluocinolone acetonide or the ester of the fluocinolone acetonide serving as the active component, and one or more auxiliary materials applied to skin; and the exterior medicine composition is characterized in that the auxiliary materials for skin include sodium calcium edetate or edetate disodium.

A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.

A detoxifying, itching relieving and sterilizing ointment comprises, by weight, 20-40 parts of Chinense Golden Larch Bark, 10-30 parts of Rhizoma Coptidis, 10-30 parts of Amur Corktree Bark, 10-30 parts of Radix Scutellariae, 10-25 parts of Rheum officinale, 15-45 parts of Sophora flavescens, 10-40 parts of Fructus Cnidii, 10-40 parts of Radix Stemonae, 10-30 parts of Spanish fly, 20-40 parts of Semen Momordicae, 10-20 parts of Boswellia carteri, 10-30 parts of myrrh, 10-30 parts of scorpion, 20-40 parts of alum, 10-30 parts of camphor, 10-30 parts of borneol, 3-10 parts of realgar, 10-15 parts of sulfur, 3-9 parts of chlordiazepoxide keone, 0.05-0.1 parts of fluocinolone acetonide, 5-15 parts of propylene glycol, 15-25 parts of glycerol, 5-15 parts of liquid paraffin, 10-20 parts of white Vaseline, 10-20 parts of stearic acid, 15-25 parts of glycerol monostearate, 5-8 parts of beeswax, 0.3-0.8 parts of triethanolamine, 0.3-0.8 parts of lauric acid and 0.2-0.5 parts of nipagin.

The application relates to the field of a medicinal preparation, and more specifically relates to a compound fluocinolone acetonide spraying agent and a preparation method thereof. The compound fluocinolone acetonide novel spraying agent comprises a solvent as well as basic remedy components and additives dissolved in the solvent; the basic remedy components comprise fluocinolone acetonide, salicylic acid, resorcinol, borneol, glycerin and dimethyl sulfoxide; additives comprise a osmotic pressure conditioning agent, a transdermal enhancer, a pH regulator and a surfactant. The compound fluocinolone acetonide novel spraying agent has the advantages of good stability in storage process, rapid effectiveness of medicament, and improved effective rate of disease treatment.

The invention relates to a synthesis method of a fluocinolone acetonide intermediate. A steroid compound with a structure I is used as an initiator to synthesize a precursor V of a glucocorticoid drug fluocinolone acetonide, Alpha-fluorine is introduced at a site C6 of the compound I, and an intermediate V is finally obtained through oxidization and introduction of fluorine at a site C9. The initiator raw material is cheap and is easy to obtain, and the synthesis method is stable and economical and reasonable. The synthesis process is as shown in the specification.

The invention discloses an externally-applied medicine for treating dermatopathy caused by pathogenic fungi, and is characterized in that the externally-applied medicine is prepared from the following medicines in parts by weight: 10-20 parts of a clotrimazole cream, 15-25 parts of a fluocinolone acetonide ointment, 0.6-1.0 part of metronidazole, 1.5-2.0 parts of chloramphenicol, 1-5 parts of borneol, 0.2-0.8 part of a rivanol powder, and 0.05-0.15 part of prednisone. Clinic experiments prove that the externally-applied medicine can safely and effectively treat the dermatopathy caused by the pathogenic fungi.

The invention discloses an externally-applied Chinese and western medicine ointment capable of treating herpes zoster and a preparation method thereof. The ointment is prepared from the following raw Chinese and western medicines by weight: 4g-6g of realgar, 1g-3g of sulfur, 2g-4g of lead oxide, 1g-3g of calomel, 1g-3g of compound of glauber-salt and liquorice, 1g-3g of compound acetylsalicylic acid powder, 1g-2g of metronidazole powder and two bottles of fluocinonide unguent, wherein each bottle contains 20g fluocinonide unguent. The Chinese and western medicine ointment is prepared according to the following steps: preparing the raw Chinese and western medicines according to the proportional relation; except the compound of glauber-salt and liquorice in the five traditional Chinese medicines, respectively grinding the rest four medicines and sieving with a 100-mesh sieve; respectively packaging the five types of traditional Chinese medicine power and the two types of western medicine powder in one bag in a vacuum manner; adding the Chinese and western medicine powder into fluocinolone acetonide unguent, and uniformly stirring to prepare the Chinese and western medicine ointment which can be used at once. The externally-applied Chinese and western medicine ointment is unique in curative effect, simple in preparation process and low in cost. More than 200 cases of herpes zoster patients clinically treated are all cured rapidly, and the curative ratio is as high as 100%, so the externally-applied Chinese and western medicine ointment is worth of further popularization.

The invention discloses an emergency treatment method for preventing deep scar caused by hydrogen fluoride burn. The method comprises the following steps of: preparing an ammonium bicarbonate chemical solution and aminosalicylic acid ointment; preparing 2 percent ammonium bicarbonate solution, i.e. adding 20g of ammonium bicarbonate reagent into a 1,000ml volumetric flask, diluting with water until the volume is 1,000ml, and uniformly mixing for later use; preparing 1 percent aminosalicylic acid ointment: weighing 1g of aminosalicylic acid, dissolving in 5g of water, adding 5ml of glycerol, uniformly stirring for later use, weighing 90g of commercial fluocinolone acetonide ointment sold in a drug store, adding the prepared reagent, stirring with a glass bar uniformly, and filling into a box for later use; and washing with massive water, performing neutralizing treatment with the prepared ammonium bicarbonate chemical solution, and applying the aminosalicylic acid ointment for treatment. By using the treatment method disclosed by the invention, severe results, such as osteoporosis formed by skeletal fluorosis caused by putrescence and ulcer due to corrosion and deep penetration of hydrogen fluoride to human skin can be effectively prevented, and permanent scar can be effectively prevented from being left.

Topically applicable compositions useful for the depigmentation of the skin contain a fluocinolone acetonide depigmenting agent, at a concentration of from 0.0001% to 0.02% by weight, of the total weight of the composition, formulated into physiologically acceptable carrier therefor.

A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.

Hyperpigmentary skin disorders, notably those associated with psoriasis or eczema, are prevented/treated by administering to individuals in need of such treatment, thus effective amounts of medicaments containing a combination of fluocinolone acetonide, hydroquinone and tretinoin, formulated into a physiologically acceptable medium therefor.

Dermatological/medicament compositions containing a combination of hydroquinone, fluocinolone acetonide and tretinoin are useful for treating the signs of photoaging of the skin.

The invention discloses clean itching relieving paste for treating non-neoplastic epithelial disorders of the vulva, belonging to the field of traditional Chinese medicine preparations. The non-neoplastic epithelial disorders of the vulva refers to a group of chronic diseases that the female vulva skin and mucous membrane tissue suffer degeneration and pigment change, and is most clinically manifested on the middle-aged women younger than 50 years old. The traditional external ointment realizes relatively slow cure and bad effect. The clean itching relieving paste disclosed by the invention is characterized by being prepared by taking the Chinese and western medicines of vitamin B1, vitamin B2, vitamin E, diethylstilbestrol, minium, clam meal and borneol as the major raw materials and taking fluocinolone acetonide ointment or testosterone propionate ointment as an auxiliary. The product is pink emulsifiable paste, and has the functions of reliving itching and coloring, softening cutin, removing necrotic tissue and promoting granulation and relieving swelling and pain; the paste can quickly permeate into the skin surface, has short course of treatment, realizes quick cure, and does not cause recurrence easily while preventing allergy and toxic side effect; and the cure cost is relatively low. The clean itching relieving paste disclosed by the invention has a simple structure.

The invention relates to the technical field of medicines, and specifically discloses a medicine for treating beriberi, which is characterized in that it includes ointment and liquid medicine, and the ointment is composed of the following components and proportions: 500-550 g of Fuchuang ointment, 30-50 g of benzoic acid 35g, salicylic acid 15-20g; the liquid medicine is composed of the following components and proportions: benzoic acid 60-70g, salicylic acid 30-40g, alcohol 500-550ml. The present invention has the following advantages: the medicine for treating beriberi of the present invention is the combined use of liquid medicine and ointment, the effect can be seen on the day of use, and the phenomenon of blisters and molting can be cured after 4 days of use, and the mycotoxins can be cleaned up to achieve full recovery. Effect.

The invention provides a high-stability compound fluocinonide tincture which takes sodium hydroxide or triethylamine as a pH regulator, and the pH of the compound fluocinonide tincture is 5.3-5.7. Thecompound fluocinonide tincture system provided by the invention is good in stability; and in a long-time storage process, impurities generated by effective components including fluocinolone acetonide, salicylic acid, resorcinol and borneol are few, and the content of the key effective component fluocinolone acetonide can be kept at a relatively high level.

Dermatological medicament compositions contain a combination of hydroquinone, fluocinolone acetonide and tretinoin and are useful for the treatment of the hyperpigmentation of pathological scars, namely, hypertrophic scars and keloidal scars.

The invention discloses an external compound tincture for treating dermatitis and a preparation method of such external compound tincture. The external compound tincture for treating the dermatitis comprises fluocinolone acetonide, salicylic acid, resorcinol, borneol, clathrate, a co-solvent, an antioxidant, a pH modifier and a solvent. Every 1000 g of tincture is prepared from, by weight, 0.1-10 g of fluocinolone acetonide, 5-100 g of salicylic acid, 20-200 g of resorcinol, 5-50 g of borneol, 1-10 g of clathrate, 2-40 g of co-solvent, 0.30-0.4 g of antioxidant, 2-10 g of pH modifier and 200-800 g of solvent. The external compound tincture for treating the dermatitis and the preparation method of such external compound tincture have the advantages that a reasonable formula and the preparation method are screened to solve the problems that the content of the fluocinolone acetonide is instable and relative substances exceed standards; with the aid of an inclusion technique and by means of an orthogonal experiment, an optimal inclusion rate, an optimal stirring speed and optimal time are determined with the content of the fluocinolone acetonide and the relative substances as indexes so as to generate an explicit and operable preparation process.